A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer

Small Cell Lung Cancer Clinical Trial

Official title:

Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00317200
• Other study ID #: HOG LUN05-99
• Status: Completed
• Phase: Phase 2
• First received: April 20, 2006
• Last updated: April 28, 2011
• Start date: April 2006
• Est. completion date: November 2007

Study information

• Verified date: April 2011
• Source: Hoosier Cancer Research Network
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Improvements in therapy for relapsed SCLC are much needed. Paclitaxel has been previously tested and found to have significant single agent activity in relapsed SCLC, including in refractory patients. Angiogenesis plays an important role in SCLC, increased VEGF levels are associated with worse outcomes. Bevacizumab, a monoclonal antibody to VEGF, increase response rates and survival when combined with chemotherapy agents compared with the chemotherapy agent alone in NSCLC, breast cancer, and colorectal cancer. Paclitaxel plus bevacizumab, in the dose and schedule proposed in this study, improves response rates and progression free survival compared with paclitaxel alone in women with metastatic breast cancer. Therefore, we will be testing the safety, feasibility, and efficacy of this regimen in patients with chemosensitive relapsed SCLC.

Description:

OUTLINE: This is a multi-center study.

Paclitaxel 90 mg/m2 IV infusion over 1 hour days 1, 8 and 15 of 28 day cycle

Plus

Bevacizumab 10 mg/kg on days 1 and 15 of 28 day cycle.

• 1 cycle = 28 days (4 weeks)

• Disease assessments will be performed per RECIST every other cycle

• After a minimum of 4 cycles or a maximum of 6 cycles of combination chemotherapy, bevacizumab monotherapy may continue until disease progression or intolerable side effects

ECOG Performance Status 0 or 1

Hematopoietic:

• White blood cell count > 3,000 mm3

• Absolute neutrophil count (ANC) > 1,500 mm3

• Platelet count > 100,000 mm3

• International normalized ration (INR) of prothrombin time ≤ 1.2

• PTT no more than 5 seconds longer than the ULN

Hepatic:

• Bilirubin < 1.5 x ULN

• Aspartate aminotransferase (AST, SGOT) < 2.5 x ULN

Renal:

• Urine protein:creatinine ratio <1.0

Cardiovascular:

• No history of myocardial infarction or angina pectoris/anginal equivalent in the last 6 months. Note: The patient may be on anti-anginal medications if the symptoms have been entirely controlled for greater than 6 months.

• No history of uncontrolled congestive heart failure or uncontrolled hypertension

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: November 2007
• Est. primary completion date: November 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologic or cytologic proof of small cell lung cancer

• Chemo-sensitive disease defined as relapsed after 60 days from completion of first line chemotherapy.

• Measurable disease according to RECIST and obtained by imaging within 28 days prior to being registered for protocol therapy.

• Must have received treatment with at least 1 but not more than 2 prior chemotherapy regimens. (At least one regimen must contain a platinum agent. Previous treatment with irinotecan is allowed.)

• Prior radiation therapy must be completed at least 21 days prior to being registered for protocol therapy, and toxicities due to radiation must have recovered to = grade 1 or baseline prior to registration.

• Prior cancer treatment must be completed at least 21 days prior to being registered for protocol therapy and the subject must have recovered from the acute toxicity effects of the regimen prior to registration.

Exclusion Criteria:

• No treatment with any investigational agent within 30 days prior to being registered for protocol therapy.

• No history or radiographic evidence of CNS involvement by head CT or MRI within 42 days prior to registration.

• No history of seizures, transient ischemic attack or stroke.

• No clinically significant infections as judged by the treating investigator.

• No other active cancer except SCLC.

• No prior treatment with topoisomerase I inhibitor.

• No contraindications to the use of paclitaxel or bevacizumab as per the investigator's clinical judgment.

• Must not have grade 3 or greater peripheral neuropathy.

• Must not have had major surgical procedure, open biopsy, or significant traumatic injury within 28 days of being registered for protocol therapy.

• No anticipation of need for major surgical procedure during the course of the study.

• Patients may not have had a minor surgical procedure, placement of an access device or fine needle aspiration within 7 days prior to being registered for protocol therapy.

• No evidence of bleeding diathesis or coagulopathy.

• No history of deep vein thrombosis or pulmonary embolism.

• No full dose/therapeutic anticoagulation with either low molecular weight heparin or unfractionated heparin or coumadin within 10 days prior to registration.

• Patients must not have been using aspirin (>325 mg/day) or another nonsteroidal anti-inflammatory medications known to inhibit platelet function on a daily basis within 10 days prior to registration on study.

• Patients must not be using any of the following drugs known to inhibit platelet function within 10 days prior to registration: dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix) and cilostazol (Pletal).

• Patients must not have a current non-healing wound or fracture.

• Patients must not have a history of or current hemoptysis.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lung Neoplasms
• Small Cell Lung Cancer
• Small Cell Lung Carcinoma

Intervention

Drug:
• Paclitaxel
Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.
• Bevacizumab
Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle

Locations

Country	Name	City	State
United States	Cancer Care Center of Southern Indiana	Bloomington	Indiana
United States	Oncology Hematology Associates of SW Indiana	Evansville	Indiana
United States	Fort Wayne Oncology & Hematology, Inc	Fort Wayne	Indiana
United States	Medical & Surgical Specialists, LLC	Galesburg	Illinois
United States	Center for Cancer Care at Goshen Health System	Goshen	Indiana
United States	Community Regional Cancer Center	Indianapolis	Indiana
United States	Indiana University Cancer Center	Indianapolis	Indiana
United States	Quality Cancer Center (MCGOP)	Indianapolis	Indiana
United States	Arnett Cancer Care	Lafayette	Indiana
United States	Medical Consultants, P.C.	Muncie	Indiana
United States	Center for Cancer Care, Inc., P.C.	New Albany	Indiana
United States	Methodist Cancer Center	Omaha	Nebraska
United States	Pennsylvania Oncology-Hematology Associates	Philadelphia	Pennsylvania
United States	Fox Chase Cancer Center Extramural Research Program	Rockledge	Pennsylvania
United States	Northern Indiana Cancer Research Consortium	South Bend	Indiana
United States	Highlands Oncology Group	Springdale	Arkansas
United States	Siteman Cancer Center	St. Louis	Missouri

Sponsors (3)

Lead Sponsor	Collaborator
Hoosier Cancer Research Network	Genentech, Inc., Walther Cancer Institute

Country where clinical trial is conducted

United States, 

References & Publications (1)

Jalal S, Bedano P, Einhorn L, Bhatia S, Ansari R, Bechar N, Koneru K, Govindan R, Wu J, Yu M, Schneider B, Hanna N. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine progression free survival(PFS) of this regimen in patients with chemosensitive relapsed small cell lung cancer (SCLC).		18 months	No
Secondary	To determine the response rate of the combination of paclitaxel and bevacizumab with chemosensitive SCLC.		18 months	No
Secondary	To determine the toxicity of the combination of paclitaxel and bevacizumab in patients with SCLC.		18 months	Yes
Secondary	To determine overall survival.		18 months	No
Secondary	To assess VEGF polymorphisms in the study population.		18 months	No

External Links

•   Hoosier Oncology Group Home Page